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Background: Head and neck squamous cell carcinomas (HNSCCs) are highly lethal epithelial tumours containing self-renewal
cancer stem cells (CSCs). CSCs in HNSCCs are strongly associated with tumour initiation, invasion, and chemoradiation resistance.
However, the important factors regulating stemness in HNSCCs remain unclear. Here, we investigated the molecular roles and
clinical significance of inhibitor of DNA binding 2 (Id2) protein to determine if it constitutes a novel therapeutic target for ablating
HNSCC cells with stemness.
Methods: We performed in vitro and in vivo studies of Id2 function and its effects on stemness using HNSCC cells. We also
examined whether Id2 expression could be used as a prognostic indicator through immunohistochemical staining of 119 human
HNSCC tumours.
Results: Expression of Id2 was higher in HNSCC cells with stemness compared with differentiated HNSCC cells. Overexpression
of Id2 increased proliferation, self-renewal, and expression of the putative stemness marker CD44 in HNSCC cells in vitro and
in vivo. In contrast, silencing of Id2 using short hairpin RNA attenuated the stemness phenotype of HNSCC cells by reducing self-
renewal, CD44 expression, cisplatin chemoresistance, and xenograft tumourigenicity. Most importantly, increased expression of
Id2 was closely associated with poorer post-treatment survival rates in HNSCC patients.
Conclusions: Inhibitor of DNA binding2 represents a novel and promising therapeutic target for treating and improving the
clinical outcomes for patients with HNSCC.
Head and neck squamous cell carcinomas (HNSCCs) are one of
several types of cancers originating from the upper aerodigestive
tract, which includes the oral cavity, pharynx, and larynx. HNSCCs
account for more than 300 000 new cases worldwide annually
(Leemans et al, 2011). Major risk factors associated with the
development of HNSCCs are smoking, alcohol consumption, and
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human papilloma virus infection (Polanska et al, 2014). Although
recent advances in diagnostic and therapeutic techniques for these
tumours have been developed, survival has not markedly improved
in the past decades because patients still frequently develop
locoregional tumour recurrences, distant metastases, and second-
ary primary tumours (Guo and Califano, 2015). Thus, an
improvement in the prognosis of patients with HNSCCs will
require a deeper understanding of the molecular mechanisms
underlying various steps in HNSCC tumourigenesis. These efforts
may even result in the development of novel therapeutic strategies
and a possible cure for HNSCCs.
Recent studies of the pathogenesis of HNSCCs have identified a
sub-population of cancer cells, termed cancer stem-like cells
(CSCs) or cancer-initiating cells. These cells are highly tumouri-
genic and resistant to conventional chemotherapy agents. They
also display features commonly associated with embryonic or adult
stem cells, such as self-renewal and multipotency (Matsui, 2016).
Notably, in a clinical setting, CSCs appear to have a critical role
in treatment resistance, resulting in tumour recurrence and
metastasis. These are common causes of high mortality in patients
with HNSCCs (Bhaijee et al, 2012). Thus, selective elimination of
these CSCs constitutes one promising approach to treating
HNSCCs.
Inhibitor of DNA binding (Id) proteins are basic helix–loop–
helix (bHLH) transcription factors. They constitute four subclasses,
which include Id1, Id2, Id3, and Id4 (Lasorella et al, 2014). Other
bHLH families regulate the transcription of various target genes,
and function as either homodimers or heterodimers (Perk et al,
2005). However, because of the destitute DNA-binding domain, Id
proteins bind to ubiquitously expressed E protein transcription
factors or tissue-restricted bHLH proteins, preventing them from
forming DNA-bound, transcriptionally active complexes (Sikder
et al, 2003). As a result, Id proteins control multiple processes
during normal development and adult life, including cell fate
determination, differentiation, and proliferation (Desprez et al,
2003). Embryonic neural stem cells completely lose their self-
renewal capacity and multipotency in the absence of Id1, Id2, and
Id3 (Jung et al, 2010; Niola et al, 2012). Inactivation of Id1 and Id3
triggers premature differentiation of neuronal stem cells in the
developing mouse brain (Riechmann and Sablitzky, 1995; Jung
et al, 2010).
Inhibitor of DNA binding proteins are often overexpressed in
many human cancers. In addition, recent genomic analyses of
cancer tissues identified various loss-of-function mutations in Id
genes, suggesting that this family may have roles as tumour
suppressors (Love et al, 2012; Richter et al, 2012). Numerous
oncoproteins, such as MYC, RAS, epidermal growth factor
(EGF), and basic fibroblast growth factor (bFGF), increase the
transcriptional activity of Id proteins as upstream regulators
(Lasorella et al, 2014). Furthermore, Id proteins are targeted for
degradation by APC/C-CDH1 and SMURF2, which are two
ubiquitin ligases that function as tumour suppressors (Wang et al,
2008; Kong et al, 2011). In addition, the expression of Id proteins
can inform the prognosis for many human cancers (Lasorella et al,
2014).
Inhibitor of DNA binding proteins may be involved in
tumourigenesis and maintenance of normal stem cell functions.
Recent reports have established that Id proteins promote the
formation of CSCs (Anido et al, 2010; O’Brien et al, 2012). In colon
CSCs, the combined expression levels of Id1 and Id3 increased
during self-renewal and tumour initiation (O’Brien et al, 2012).
Additionally, conditional deletion of Id1, Id2, and Id3 in tumour
cells decreased glioma stem cell populations (Anido et al, 2010).
However, it is unclear whether Id proteins regulate CSCs in
HNSCC. Here, we report that Id2 is essential for the maintenance
of HNSCC CSCs and constitutes a potential therapeutic target for
selectively eliminating HNSCC CSCs.
MATERIALS AND METHODS
Cell lines and reagents. We used three human HNSCC cell lines
for this study. Of these, two HNSCC cell lines (FaDu and
SNU1041) were obtained from the Korean Cell Line Bank and
cultured in DMEM containing 10% FBS and 1% penicillin/
streptomycin. The third cell line (KU-SCC-3) was obtained from a
primary culture of human HNSCC tumours. Briefly, the KU-SCC-
3 cells were isolated from patients’ primary HNSCC tumours and
placed into a serum-free conditional medium containing Dulbec-
co’s modified Eagle’s medium and Ham’s F12 medium (DMEM/
F12) supplemented with human recombinant bFGF (10 ngml 1;
R&D Systems, Minneapolis, MN, USA), N2 supplement (Gibco,
Franklin Lakes, NJ, USA), and EGF (10 ngml 1; R&D Systems).
Cisplatin was purchased from Sigma-Aldrich (St Louis, MO, USA).
The following primary antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA): anti-Id2, anti-Oct4, anti-
Sox2, anti-CD44, anti-cyclin A, anti-cyclin B, anti-cyclin D1, and
anti-ATP-binding cassetteG2 (ABCG2). The following secondary
antibodies were purchased from Jackson ImmunoResearch
Laboratories (West Grove, PA, USA): anti-rabbit IgG and anti-
mouse IgG.
Plasmid transfection. Short hairpin RNA (shRNA) targeting
human Id2 was purchased from Sigma-. The following constructs
were kindly provided by Prof. Kim H (Korea University, Seoul,
South Korea): pBabe-Id2, Id2 overexpression, and pBabe-scramble.
The shRNA-Id2 vector was transfected into KU-SCC-3 cells using
a microporator apparatus. Transfection of the Id2 overexpression
vector was performed using the PolyExpress Transfection Reagent
(Excellgen, Rockville, MD, USA) according to the manufacturer’s
instructions. Cells were selected for 2 weeks using the antibiotic
puromycin (Calbiochem, Darmstadt, Germany) for the shId2
vector and G418 (Duchefa Biochemie, BH Haarlem, Netherlands)
for the Id2 overexpression vector. For knockdown of cyclin A,
small interfering RNAs were purchased from Bioneer (Daejeon,
South Korea) and transfected using Lipofectamine (Life Technol-
ogies, Carlsbad, CA, USA).
Quantitative reverse transcription–polymerase chain reaction.
Total RNA (0.5 mg) was used to synthesise cDNA with a ReverTra
Ace qPCR RT Master Mix and a gDNA Remover Kit (Toyobo Co.
Ltd, Osaka, Japan) according to the manufacturer’s instructions.
For semi-quantitative reverse transcription–polymerase chain
reaction (RT-PCR), the synthesised cDNA was added to a mixture
of 1U of Taq DNA polymerase (Lucigen, Middleton, WI, USA)
and gene-specific primers. This was amplified using the T100
Thermal Cycler (Bio-Rad Laboratories, Hercules, IN, USA). PCR
products were separated by electrophoresis on 1.5% agarose gels
and detected under ultraviolet light (Bio-Rad, Hercules, CA, USA).
Real-time RT–PCR analysis was performed on a LightCycler 480
Real-Time Detection System (Roche Diagnostics, Indianapolis, IN,
USA) using 2 LightCycler 480 SYBR-Green Master Mix (Roche
Diagnostics). The sequences of human-specific primers used are:
Id2 – forward, 50-TGGACTCGCATCCCACTATT-30 and reverse,
50-ATTCAGAAGCCTGCAAGGAC-30; NGFR (nerve growth fac-
tor receptor) – forward, 50- CTGCTGTTGCTGCTTCTGGG-30;
reverse, 50- GGCTCACACACGGTCTGGTT-30; CK-4 – forward,
50-AGGAGGTCACCATCAACCAG-30 and reverse, 50-ACCTTG
TCGATGAAGGAGGC-30.
Western blot analysis. Cells were lysed in a lysis buffer (50mM
Tris-HCl of pH 7.5, 2mM EDTA, 150mM NaCl, 1% Triton X-100,
1% sodium deoxycholate, 0.1% SDS, and a mixture of protease and
phosphatase inhibitors) on ice for 30min. The lysates were
centrifuged at 14 000 r.p.m. at 4 1C for 20min, and the protein
concentrations were determined using the Bradford protein assay
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(Bio-Rad Laboratories). Sodium dodecyl sulfate–polyacrylamide
gel electrophoresis was used to separate the proteins, which were
subsequently transferred to a polyvinylidene fluoride membrane
(Millipore, Billerica, MA, USA). The membrane was blocked with
5% non-fat dry milk in Tris-buffered saline containing 0.1%
Tween-20 (TBST) at room temperature for 1 h, and incubated with
primary antibodies overnight at 4 1C. The membrane was washed
the next day with TBST and incubated with the corresponding
horseradish peroxidase-conjugated secondary antibody for 1 h.
Finally, immunoreactive bands were visualised by enhanced
chemiluminescence detection.
Immunocytochemistry. Spheres were fixed in 4% paraformalde-
hyde, embedded and frozen in optimal cutting temperature
compound, and cryosectioned (5mm thick). Sections were
immunostained with antibodies against Id2 (1 : 50; Santa Cruz
Biotechnology) overnight at 4 1C. After washing, sections were
incubated with Cy3-conjugated anti-mouse secondary antibodies.
Nuclei were counterstained with 40,6-diamidino-2-phenylindole
(DAPI; 1 mgml 1). Slides were photographed using an optical or
confocal microscope (Zeiss, Oberkochen, Germany).
Cell growth and proliferation assay. To evaluate cell growth,
2 104 cells were plated and grown in media supplemented with
FBS. Every 2 days, cells were detached with trypsin and the total
number of cells was counted. Cell proliferation was measured using
the colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethox-
yphenyl)-2-(4-sulphophenyl)-2H-tetrazolium (MTS) assay (Pro-
mega, Madison, WI, USA). Briefly, 5 104 cells were seeded into a
96-well plate. After incubation for 24 h, 20 ml of MTS solution was
added to each sample well in 100 ml of culture medium and
incubated at 37 1C for 2 h. Colorimetric analysis was performed
using an ELISA Plate Reader (Molecular Devices, Sunnyvale, CA,
USA) at 490 nm.
Flow cytometry for detection of CD44 levels. Spheroid cells were
dissociated into single cells, washed, and suspended in PBS. Cells
were incubated with an anti-CD44 primary antibody and a FITC-
labelled secondary antibody, and subjected to flow cytometry using
a FACSCalibur machine (BD Biosciences, San Jose, CA, USA).
Sphere-forming assay. To assess self-renewal in vitro, cells were
dissociated into single cells, seeded into a 24-well plate at a density
of 500 cells per well, and cultured in serum-free media with EGF
and bFGF supplementation every other day. Spheres with a
diameter exceeding 50 mm were counted after 7 days.
Cell viability assay for cisplatin. Cells were plated in a 96-well
plate at a density of 1 104 cells per well, and then treated with
either cisplatin at various concentrations or DMSO. Two days later,
10 ml of 3-(4,4-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) solution (5mgml 1 in PBS) was added to each well
and incubated at 37 1C for 2 h. The absorbance was measured using
a SpectraMax 190 (Molecular Devices) at a wavelength of 570 nm.
In vivo xenograft experiments. All animal studies were approved
by the Institutional Animal Care and Use Committee of Konkuk
University. To assess the tumourigenicity of HNSCC cells treated
with Id2 shRNA or control shRNA, dissociated spheroid cells were
counted, resuspended in 100 ml of Matrigel, and injected
subcutaneously into the flank of 8-week-old female BALB/c nude
mice using a 22-gauge needle. Engrafted mice were inspected
weekly for signs of tumour appearance by visual observation and
palpation for 8 weeks following the injection.
Patient sample immunohistochemistry. Immunohistochemistry
of HNSCC patients’ tissues was approved by the local institutional
review board. HNSCC samples were collected from patients who
had given informed consent. Formalin-fixed and paraffin-
embedded tissues from 119 HNSCC lesions were retrieved from
the archives of the Pathology Department of Chungnam National
University Hospital in Korea. These included 44 samples from the
oral cavity, 17 from the oropharynx, 48 from the larynx, and 10
from the hypopharynx. Paraffin-embedded tissues were section at
4 mm and used for immunohistochemical staining according to the
methods provided in the Vectastain ABC Kit (Vector, Burlingame,
CA, USA). The intensity of immunostaining was then analysed.
Briefly, the intensity was scored as grade 0 when no positive cells
were identified, grade 1 with weak staining, grade 2 with moderate
staining, and grade 3 with strong staining. For statistical analyses,
negative staining was considered to be grade 0 or grade 1 staining,
and positive staining was considered to be grade 2 or grade 3
staining. All slides were scored by at least two pathologists who had
no clinical information about the patients.
Statistics. All analyses were performed using SPSS 12.0 (SPSS Inc.,
Chicago, IL, USA). Statistical significance was assessed using a two-
tailed Student’s t-test or ANOVA test. The association between Id2
expression and clinical parameters was analysed by Fisher’s exact
test. The survival analysis in human and mice samples was
performed using the Kaplan–Meier survival curve and log-rank
test. P*o0.05 was considered statistically significant.
RESULTS
Id genes are differentially expressed in HNSCC cells. First, we
identified which subtype of the four Id gene families (Id1–Id4) is
enriched in HNSCC cells. We performed qRT–PCR to examine the
transcript levels of various Id genes in spheroid form and the
attached form of HNSCC cells, because any cells that produce the
spheroid form under serum-free conditioned media have the
characteristics of CSCs (Jeon et al, 2008; Lim et al, 2011).
Interestingly, Id2 mRNA levels were markedly elevated in spheroid
form of HNSCC cells compared with the expression of the other Id
genes (Supplementary Figure S1). Thus, we hypothesise that Id2
expression may correlate with phenotypic characteristics associated
with HNSCC CSCs, and performed the further experiments.
Overexpression of Id2 accelerates HNSCC cell growth via cyclin
A activation. To evaluate the effect of Id2 overexpression on the
proliferation of HNSCC cells, we generated Id2-overexpressing
FaDu and SNU1041 cells (Supplementary Figure S2A). Id2
overexpression significantly increased the growth of FaDu
(Figure 1A and Supplementary Figure S2B) and SNU 1041 cells
(Figure 1B and Supplementary Figure S2C) in vitro. It also
significantly increased the sizes and weights of tumours generated
after inoculation of mice with transfected FaDu cells (Figure 1C).
Next, we determined whether any cyclins correlated with the
increased cell proliferation of the Id2-overexpressing FaDu and
SNU1041 cells. We found that an elevation in cyclin A expression
was observed in Id2-overexpressing cells (Figure 1D and
Supplementary Figure S2D). Furthermore, siRNA-mediated deple-
tion of cyclin A in Id2-overexpressing FaDu cells (Supplementary
Figure S2E) decreased the proliferation of tumours produced by
Id2-overexpressing FaDu cells (Supplementary Figure S2F and G).
Therefore, the proliferation activity of Id2 seems to be mediated, in
part, through cyclin A-driven cell proliferation. Taken together,
ectopic Id2 expression promotes the tumour growth of HNSCC
cells through the activation of cyclin A.
Overexpression of Id2 enhances stemness feature of HNSCC
cells. One of the key traits of a CSC is its self-renewal capacity (Al-
Hajj et al, 2003). To examine this in HNSCC, we compared the
self-renewal capacity of Id2-overexpressing cells to control cells
using a sphere-forming assay. The number of spheres was
significantly higher in Id2-overexpressing HNSCC cells compared
with control cells (Figure 2A and B). We then compared the
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expression levels of stem cell markers, including OCT4 and SOX2,
in Id2-overexpressing cells versus control cells. We found that the
protein levels of SOX2 were significantly higher in Id2-over-
expressing HNSCC cells compared with control cells
(Supplementary Figure S3A). Recently, Kang et al (2015) reported
that NGFR and CK4 were suggested as stemness and differentia-
tion markers in tonsillar epithelial stem cell, respectively. Thus, we
examined mRNA levels of these genes in scrambled- and Id2-
overexpressing HNSCC cells. As a result, transcriptional levels of
NGFR increased in Id2-overexpressing HNSCC cells, and that of
CK5 decreased in same cells, compared with that in scrambled
HNSCC cells (Supplementary Figure S3B). Previously, putative
HNSCC CSCs have been isolated based on CD44 expression,
which has been proposed to be a molecular marker for these cells
(Prince et al, 2007). Thus, we investigated whether there were
differences in CD44 expression between Id2-overexpressing cells
and control cells. Id2-overexpressing HNSCC cells displayed
higher levels of CD44 expression compared with control cells
in vitro and in vivo (Figure 2C and D). Taken together, our data
suggest that Id2 expression may enhance stemness feature in
HNSCC cells.
Knockdown of Id2 gene expression reduces stemness of primary
HNSCC cells. Inhibitor of DNA binding 2 expression levels are
also increased in the spheroid form of primary HNSCC cells
generated from the HNSCC tumour tissue (Figure 3A and B and
Supplementary Figure S4A). To elucidate the role of Id2 in HNSCC
CSC maintenance, we examined the effects of Id2 knockdown on
the stemness of primary HNSCC cells (Supplementary Figure S4B).
Targeting Id2 with shRNA reduced the efficiency of sphere
formation and decreased the expression of SOX2 and CD44 in
primary HNSCC cells (Figure 3C and D and Supplementary Figure
S5). These data demonstrate that depletion of Id2 specifically
disrupts stemness traits of primary HNSCC cells.
Id2 expression is associated with cisplatin resistance in HNSCC
cells. Cancer stem cells are believed to be highly resistant to
conventional chemotherapeutic drugs (Dean et al, 2005).
Therefore, we examined whether Id2 has a role in chemoresistance
in HNSCC cells. Cell viability of Id2-overexpressing HNSCC cells
after cisplatin treatment was significantly higher than in scrambled
control cells (Supplementary Figure S6A). In addition, a reduction
in Id2 expression in primay HNSCC cells markedly decreased
chemoresistance to cisplatin compared with the scrambled control
cells (Supplementary Figure S6B). One of the mechanisms
mediating CSC chemoresistance is overexpression of the ATP-
binding cassette (ABC) transporters, which regulate the flux of
chemotherapeutic agents across the plasma membrane (Cui et al,
2015). Of these ABC transporters, ABCG2 overexpression is
associated with multidrug resistance and cancer progression in
HNSCC (Zhao et al, 2015). Thus, we examined whether Id2
chemoresistance correlates with ABCG2 expression in HNSCC
cells. Interestingly, we found that Id2 knockdown reduced ABCG2
expression in HNSCC cells (Supplementary Figure S6C). These
data suggest that Id2 expression is associated with cisplatin
resistance in HNSCC cells.
Knockdown of Id2 suppresses HNSCC tumour growth in a
xenograft mouse model. To investigate the effect of Id2 on the
tumourigenicity of HNSCC cells in vivo, we used a xenograft
model to assess tumour formation after knockdown of Id2. We
subcutaneously injected different amounts of HNSCC-shId2 or
HNSCC-scramble shRNA cells (5 103 or 5 104 cells) into
nude mice. Surprisingly, even 5 103 HNSCC-scramble shRNA
cells were sufficient to initiate tumour formation. However, none
of the mice injected with 5 103 HNSCC-shId2 cells exhibited
visible tumour formation (Figure 4A). In addition, the average
weight of tumours generated in mice after inoculation with
5 104 HNSCC-shId2 cells was significantly lower compared
with the control groups (Figure 4B). Furthermore, mice
inoculated with HNSCC-shId2 cells had significantly increased
survival rates compared with the control groups (Figure 4C).
Taken together, our findings suggest that Id2 has an important
role in HNSCC cells tumour initiation in a xenograft mouse
model.
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Id2 expression is a valuable prognostic indicator in patients with
HNSCC. To address whether Id2 expression is clinically relevant
in HNSCC patients, 119 samples from patients with primary
HNSCCs were evaluated using antibodies against Id2
(Supplementary Table S1). Immunohistochemical study revealed
that specific Id2 protein staining was found in the cytoplasm and
nucleus of tumour cells (Supplementary Figure S7) HNSCC
patients displaying high levels of Id2 expression had significantly
lower survival rates compared with those with lower expression
levels (Po0.001) (Figure 5A and B). The median 5-year overall
and cancer-specific survival rates for patients possessing tumours
with high and low Id2 expression were 39.9% and 84.2% and 42.6%
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and 92.8%, respectively (Po0.001). The association of various
clinicopathological factors influencing the prognosis of HNSCC
patients with Id2 expression was examined (Supplementary Table
S2 and Tables 1 and 2). Univariate analysis showed a statistically
significant increase in Id2 expression in advanced tumour stages
(T), advanced AJCC (American Joint Committee on Cancer)
stages, poor histologic grades, and in the presence of lymph node
metastasis (Supplementary Table S2). Multivariate analysis showed
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Id2 expression (N¼ 119). (B) Disease-specific survival rates based on Id2 expression (N¼ 119).
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that the presence of lymph node metastases was independent of
high Id2 expression (Po0.01) (Table 1). Today, the most
commonly used indicator to predict the prognosis of patients with
HNSCC after primary treatment in a clinical setting is the AJCC
staging system. Therefore, we evaluated whether Id2 expression
predicts the survival rates of HNSCC patients after treatment
more reliably than the AJCC system. Notably, we found that the
intensity of Id2 expression was better than the AJCC system at
predicting the likelihood of survival in HNSCC patients after
primary treatment (Table 2). Taken together, our data suggest
that Id2 expression is a valuable prognostic indicator for these
patients.
DISCUSSION
Since the discovery of HNSCC CSCs by Prince et al (2007), some
proteins, including those on the cell surface, are being investigated
as potential molecular markers of HNSCC CSCs. However, there is
a paucity of data regarding the intracellular signalling molecules
specific to CSCs and the signalling pathways controlling their
stemness. Cancer stem cells share characteristics with normal
tissue stem cells, such as self-renewal and multipotency. Thus, the
dysregulation of pathways required to maintain stemness in
normal stem cells may contribute to the development of CSCs,
and key factors contributing to this dysregulation may provide a
critical clue to the mechanisms of CSC genesis.
In embryonic and somatic stem cells, in addition to their
progenitors, Id family members are required to preserve stem cell
identity and prevent premature differentiation (Massari and
Murre, 2000). In embryonic stem cells, pluripotency is sustained
by bone morphogenetic protein 4-mediated expression of Id genes
via SMAD signalling (Ying et al, 2003). Additionally, in neural
stem cells and their progenitors, multiple Id family members
maintain stem cell identities (Sullivan et al, 2016). Also, the
epithelium of the distal tip of the lung expresses Id2 and contains
multipotent embryonic progenitors (Rawlins et al, 2009).
As mentioned in the Introduction, Id genes are frequently
dysregulated in many types of human neoplasms. They function as
‘hubs’ for the crosstalk of multiple cancer signalling pathways. In
head and neck cancers, Id protein immunoreactivity was observed
in the majority of malignant keratinocytes in the most poorly
differentiated sections, while reduced staining was found in well-
differentiated tumours (Langlands et al, 2000). Id1 protein
expression also correlates with lymph node status, indicating that
increased Id expression may be related to the metastatic behaviour
of human oral SCC (Dong et al, 2010). Patients with increased Id2
expression levels had poorer overall survival rates than those with
low Id2 levels in nasopharyngeal carcinoma (Liu et al, 2012). This
suggests that overexpression of Id2 protein is an unfavourable
prognostic factor that indicates likely cell proliferation in
nasopharyngeal carcinoma.
These aforementioned studies indicated that Id proteins are
likely to be an important and intrinsic determinant of CSCs,
possibly conferring traits associated with both cancer cells and
normal stem cells.
To date, possible functions for Id proteins in CSCs have been
explored in various solid tumours, including colon cancer, glioma,
breast cancer, and prostate cancer. In colon CSCs, the combined
expression of Id1 and Id3 increased both self-renewal and tumour
initiation (O’Brien et al, 2012). Meanwhile, Id4 induced expression
of glioma stem cell markers, likely through the activation of cyclin
E and Notch signalling (Jeon et al, 2008). Furthermore, Id1 was
found to be a key transcriptional regulator for multiple tumour-
promoting pathways in glioblastoma (Anido et al, 2010). The four
Id genes are located on different chromosomes and have different
expression patterns and functions. Studies of Id2 and its potential
roles in CSC genesis suggested that a link between Id2 expression
and CSC phenotypes is unlikely. However, two conflicting articles
regarding the function of Id2 with respect to CSCs was recently
published. Dong et al (2016) suggested that Wnt/b-catenin
signalling mediated hypoxia-induced self-renewal potential of
colorectal CSCs by reactivating Id2 expression. In contrast, Ghisi
et al (2016) showed that low endogenous Id2 expression is
associated with leukaemia stem cell enrichment, while Id2
overexpression inhibits the initiation and growth of mixed lineage
leukaemia-AF9 leukaemia. Thus, it is still poorly understood how
Id2 influences CSCs. In this study, we show for the first time that
Id2 expression may promote the establishment and maintenance of
stemness in CSCs generated from HNSCC cell lines and primary
cultures of HNSCC tissues. Our findings establish that over-
expression of Id2 increases self-renewal and chemoresistance of
differentiated HNSCC cells. Moreover, silencing this gene in
primary HNSCC cells results in a critical loss of tumour-initiating
potential in xenograft mouse models.
It has been suggested that Id proteins control normal and
abnormal cell cycle progression, by binding to important cell cycle
regulatory proteins (Zebedee and Hara, 2001). Interestingly, our
study revealed that Id2 increased cyclin A expression. Liu et al
(2000) showed that wild-type Id2 controlled the activity of the
cyclin A promoter in A549 lung epithelial cells, implying that Id2
could affect cell-cycle gene transcription. Mechanistic insights into
the role of Id2 regulating cell cycle of HNSCC cells will be needed
for further studies. Several Id-dependent targets are implicated in
stem cell renewal, such as NANOG, HES1, NOTCH, SOX2, and
LIF (Lasorella et al, 2014). Of these, Galatro et al (2013) showed
that Id4 expression is associated with the induction of SOX. Jeon
et al (2011) also demonstrated that Id4 inhibits miR-9*-mediated
suppression of SOX2, which leads to increased glioma stem cell
potential and chemoresistance. In addition, our previous study
showed that SOX2 has a crucial role in the genesis and
maintenance of HNSCC CSCs (Lee et al, 2014). In the present
study, overexpression of Id2 increased SOX2 expression. Thus, Id2
may promote the stemness of HNSCC cells through SOX2
Table 1. Multivariate analysis of the relationship between Id2
expression and clinicopathologic factors
Factors b (s.e.) P-value Exp (b) 95.0% CI
Advanced T stage 0.119 (0.734) 0.872 1.126 (0.267, 4.750)
Lymph node metastasis 2.539 (0.666) 0.000a 12.673 (3.435, 46.757)
Advanced AJCC stage 0.232 (0.910) 0.799 1.261 (0.212, 7.508)
Poor histologic grade 1.039 (0.571) 0.069 2.827 (0.924, 8.650)
Abbreviations: AJCC¼American Joint Committee on Cancer; CI¼ confidence interval;
Exp(b)¼Odds ratio; Id2= inhibitor of DNA binding 2.
aPo0.05.
Table 2. Multivariate Cox’s regression analysis of disease-
specific death events related to 119 HNSCC patients
Parameters RR 95% CI P-value
Age 0.924 0.481–1.774 0.812
Sex 0.453 0.130–1.586 0.216
Advanced T stage 0.649 0.320–1.314 0.229
Lymph node metastasis 1.276 0.546–2.980 0.573
Advanced AJCC stage 4.639 1.119–19.240 0.034a
Poor histologic grade 6.193 1.433–26.760 0.015a
Intense Id2 expression 5.085 1.647–15.701 0.005a
Abbreviations: AJCC¼American Joint Committee on Cancer; CI¼ confidence interval;
Id2¼ inhibitor of DNA binding 2; RR¼ ratio of risk.
aPo0.05.
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activation. Further verification about these relationship will be
needed.
One particularly notable finding from our study is the
importance of Id2 expression as a prognostic factor. In a clinical
setting, physicians must predict the prognosis of HNSCC patients
before and after treatment using the TNM staging system,
which assesses the primary tumour size (T), the presence of
lymph node metastasis (N), and the presence of distant metastasis
(M). To our knowledge, this system is the most commonly used
assay for predicting clinical outcomes for HNSCC patients.
However, patients with early-stage cancer (stage I) may die
because of cancer recurrence, while patients with advanced-
stage cancer (stage IV) may be cured without cancer recurrence.
Thus, the TNM staging system has clear limitations. The present
study compared the accuracy of TNM staging with the use of
Id2 expression strength for predicting the prognosis of HNSCC
patients. Our results suggest that Id expression is a better
indicator of patient survival compared with the TNM staging
system.
Recent developments in identifying CSCs in solid tumours may
provide tailored approaches to targeting CSCs. Recently, various
intracellular factors and signalling pathways that maintain
stemness in CSCs have been actively discussed. Therefore, as this
study has identified Id2 as a novel factor regulating HNSCC CSCs,
future efforts should explore the development of a therapeutic
agent targeting Id2 as a potential treatment for HNSCC.
ACKNOWLEDGEMENTS
This study was supported by a National Research Foundation of
Korea (NRF) grant funded by the Korean government (MEST)
(No. 2015R1A2A2A01006688 and NRF-2016R1A5A2012284 to
YCL, No. 2014R1A1A1004203 to WJB, and No. 2016R1A2A2A
05005220 to BSK). This study was also supported by the Korea
Health Technology R&D Project through the Korea Health
Industry Development Institute (KHIDI), funded by the Ministry
of Health & Welfare, Republic of Korea (HI15C2807 to YCL).
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003)
Prospective identification of tumorigenic breast cancer cells. Proc Natl
Acad Sci USA 100: 3983–3988.
Anido J, Sa´ez-Borderı´as A, Gonza`lez-Junca` A, Rodo´n L, Folch G,
Carmona MA, Prieto-Sa´nchez RM, Barba I, Martı´nez-Sa´ez E, Prudkin L,
Cuartas I, Ravento´s C, Martı´nez-Ricarte F, Poca MA, Garcı´a-Dorado D,
Lahn MM, Yingling JM, Rodo´n J, Sahuquillo J, Baselga J, Seoane J (2010)
TGF-b receptor inhibitors target the CD44(high)/Id1(high) glioma-
initiating cell population in human glioblastoma. Cancer Cell 18: 655–668.
Bhaijee F, Pepper DJ, Pitman KT, Bell D (2012) Cancer stem cells in head and
neck squamous cell carcinoma: a review of current knowledge and future
applications. Head Neck 34: 894–899.
Cui H, Zhang AJ, Chen M, Liu JJ (2015) ABC transporter inhibitors in
reversing multidrug resistance to chemotherapy. Curr Drug Targets 16:
1356–1371.
Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat
Rev Cancer 5: 275–284.
Desprez PY, Sumida T, Coppe´ JP (2003) Helix–loop–helix proteins in
mammary gland development and breast cancer. J Mammary Gland Biol
Neoplasia 8: 225–239.
Dong HJ, Jang GB, Lee HY, Park SR, Kim JY, Nam JS, Hong IS (2016) The
Wnt/b-catenin signaling/Id2 cascade mediates the effects of hypoxia on
the hierarchy of colorectal-cancer stem cells. Sci Rep 6: 22966.
Dong Z, Liu S, Zhou C, Sumida T, Hamakawa H, Chen Z, Liu P, Wei F (2010)
Overexpression of Id-1 is associated with tumor angiogenesis and
poor clinical outcome in oral squamous cell carcinoma. Oral Oncol 46:
154–157.
Galatro TF, Uno M, Oba-Shinjo SM, Almeida AN, Teixeira MJ, Rosemberg S,
Marie SK (2013) Differential expression of ID4 and its association with
TP53 mutation, SOX2, SOX4 and OCT-4 expression levels. PLoS One 8:
e61605.
Ghisi M, Kats L, Masson F, Li J, Kratina T, Vidacs E, Gilan O, Doyle MA,
Newbold A, Bolden JE, Fairfax KA, de Graaf CA, Firth M, Zuber J,
Dickins RA, Corcoran LM, Dawson MA, Belz GT, Johnstone RW (2016)
Id2 and E proteins orchestrate the initiation and maintenance of MLL-
rearranged acute myeloid leukemia. Cancer Cell 30: 59–74.
Jeon HM, Jin X, Lee JS, Oh SY, Sohn YW, Park HJ, Joo KM, Park WY,
Nam DH, DePinho RA, Chin L, Kim H (2008) Inhibitor of differentiation
4 drives brain tumor-initiating cell genesis through cyclin E and notch
signaling. Genes Dev 22: 2028–2033.
Jeon HM, Sohn YW, Oh SY, Kim SH, Beck S, Kim S, Kim H (2011) ID4
imparts chemoresistance and cancer stemness to glioma cells by
derepressing miR-9*-mediated suppression of SOX2. Cancer Res 71:
3410–3421.
Jung S, Park RH, Kim S, Jeon YJ, Ham DS, Jung MY, Kim SS, Lee YD,
Park CH, Suh-Kim H (2010) Id proteins facilitate self-renewal and
proliferation of neural stem cells. Stem Cells Dev 19: 831–841.
Kang SC, Kannan N, Zhang L, Martinez V, Rosin MP, Eaves CJ (2015)
Characterization of epithelial progenitors in normal human palatine
tonsils and their HPV16 E6/E7-induced perturbation. Stem Cell Rep 8:
1210–1225.
Kong Y, Cui H, Zhang H (2011) Smurf2-mediated ubiquitination and
degradation of Id1 regulates p16 expression during senescence. Aging cell
10: 1038–1046.
Langlands K, Down GA, Kealey T (2000) Id proteins are dynamically
expressed in normal epidermis and dysregulated in squamous cell
carcinoma. Cancer Res 60: 5929–5933.
Lasorella A, Benezra R, Iavarone A (2014) The ID proteins: master
regulators of cancer stem cells and tumour aggressiveness. Nat Rev Cancer
14: 77–91.
Lee SH, Oh SY, Do SI, Lee HJ, Kang HJ, Rho YS, Bae WJ, Lim YC (2014)
SOX2 regulates self-renewal and tumorigenicity of stem-like cells
of head and neck squamous cell carcinoma. Br J Cancer 111:
2122–2130.
Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of
head and neck cancer. Nat Rev Cancer 11: 9–22.
Lim YC, Oh SY, Cha YY, Kim SH, Jin X, Kim H (2011) Cancer stem cell traits
in squamospheres derived from primary head and neck squamous cell
carcinomas. Oral oncol 47: 83–91.
Liu J, Shi W, Warburton D (2000) A cysteine residue in the helix–loop–helix
domain of Id2 is critical for homodimerization and function. Biochem
Biophys Res Commun 273: 1042–1047.
Liu Z, Chen J, Luo W, Yang H, Wu A, Zhen Y, Yu X, Wang H, Yao K, Li X,
Fang W (2012) Overexpressed DNA-binding protein inhibitor 2 as an
unfavorable prognosis factor promotes cell proliferation in
nasopharyngeal carcinoma. Acta Biochim Biophys Sin (Shanghai) 44:
503–512.
Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH,
Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS,
Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM,
Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A,
Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB,
Dave SS (2012) The genetic landscape of mutations in Burkitt lymphoma.
Nat Genet 44: 1321–1325.
Massari ME, Murre C (2000) Helix–loop–helix proteins: regulators of
transcription in eucaryotic organisms. Mol Cell Biol 20: 429–440.
Matsui WH (2016) Cancer stem cell signaling pathways. Medicine (Baltimore)
95: S8–S19.
Niola F, Zhao X, Singh D, Castano A, Sullivan R, Lauria M, Nam HS,
Zhuang Y, Benezra R, Di Bernardo D, Iavarone A, Lasorella A (2012) Id
proteins synchronize stemness and anchorage to the niche of neural stem
cells. Nat Cell Biol 14: 477–487.
Id2 regulates stemness of HNSCC cells BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.373 1817
O’Brien CA, Kreso A, Ryan P, Hermans KG, Gibson L, Wang Y, Tsatsanis A,
Gallinger S, Dick JE (2012) ID1 and ID3 regulate the self-renewal capacity
of human colon cancer-initiating cells through p21. Cancer Cell 21:
777–792.
Perk J, Iavarone A, Benezra R (2005) Id family of helix–loop–helix proteins in
cancer. Nat Rev Cancer 5: 603–614.
Polanska H, Raudenska M, Gumulec J, Sztalmachova M, Adam V, Kizek R,
Masarik M (2014) Clinical significance of head and neck squamous cell
cancer biomarkers. Oral Oncol 50: 168–177.
Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P,
Weissman IL, Clarke MF, Ailles LE (2007) Identification of a
subpopulation of cells with cancer stem cell properties in head and neck
squamous cell carcinoma. Proc Natl Acad Sci USA 104: 973–978.
Rawlins EL, Clark CP, Xue Y, Hogan BL (2009) The Id2þ distal tip lung
epithelium contains individual multipotent embryonic progenitor cells.
Development 136: 3741–3745.
Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B (2012)
Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by
integrated genome, exome and transcriptome sequencing. Nat Genet 44:
1316–1320.
Riechmann V, Sablitzky F (1995) Mutually exclusive expression of two
dominant-negative helix–loop–helix (dnHLH) genes, Id4 and Id3, in the
developing brain of the mouse suggests distinct regulatory roles of these
dnHLH proteins during cellular proliferation and differentiation of the
nervous system. Cell Growth Differ 6: 837–843.
Sikder HA, Devlin MK, Dunlap S, Ryu B, Alani RM (2003) Id proteins in cell
growth and tumorigenesis. Cancer Cell 3: 525–530.
Sullivan JM, Havrda MC, Kettenbach AN, Paolella BR, Zhang Z, Gerber SA,
Israel MA (2016) Phosphorylation Regulates Id2 degradation and
mediates the proliferation of neural precursor cells. Stem Cells 34:
1321–1331.
Wang X, Di K, Zhang X, Han HY, Wong YC, Leung SC, Ling MT (2008) Id-1
promotes chromosomal instability through modification of APC/C
activity during mitosis in response to microtubule disruption. Oncogene
27: 4456–4466.
Ying QL, Nichols J, Chambers I, Smith A (2003) BMP induction of Id proteins
suppresses differentiation and sustains embryonic stem cell self-renewal in
collaboration with STAT3. Cell 115: 281–292.
Zebedee Z, Hara E (2001) Id proteins in cell cycle control and cellular
senescence. Oncogene 20: 8317–8325.
Zhao L, Ren Y, Tang H, Wang W, He Q, Sun J, Zhou X, Wang A (2015)
Deregulation of the miR-222-ABCG2 regulatory module in tongue
squamous cell carcinoma contributes to chemoresistance and enhanced
migratory/invasive potential. Oncotarget 6: 44538–44550.
This work is published under the standard license to publish agree-
ment. After 12 months the work will become freely available and
the license terms will switch to a Creative Commons Attribution-
NonCommercial-Share Alike 4.0 Unported License.
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
BRITISH JOURNAL OF CANCER Id2 regulates stemness of HNSCC cells
1818 www.bjcancer.com |DOI:10.1038/bjc.2017.373
